Clearside Biomedical

Clearside Biomedical EBIT per Share

Delisted

The EBIT per Share of Clearside Biomedical (CLSD) as of Nov 20, 2026 is -5.87 USD. In the previous year, EBIT per Share was -6.03 USD — a change of -2.64% (higher).

EBIT per Share

-5.87USD

YoY

-2.64%

Last updated:

EBIT per Share of Clearside Biomedical is 2024 -5.87 USD. EBIT per Share of Clearside Biomedical was 2023 -6.03 USD. It decreases by -2.64% higher compared to the previous year.

The Clearside Biomedical EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2023
-6.03 USD
Jan 1, 2024
-5.87 USD
Jan 1, 2025 (e)
-3.28 USD
Jan 1, 2026 (e)
-2.90 USD
Jan 1, 2027 (e)
-2.90 USD
Jan 1, 2028 (e)
-2.57 USD
Jan 1, 2029 (e)
8.75 USD
Jan 1, 2030 (e)
19.73 USD
The Clearside Biomedical EBIT per Share history
YEAREBIT per ShareYoY
est19.73USD+125.51%
est8.75USD-440.43%
est-2.57USD-11.47%
est-2.90USD0.00%
est-2.90USD-11.39%
est-3.28USD-44.20%
-5.87USD-2.64%
-6.03USD-20.08%
-7.54USD+4,759.66%
-0.16USD-97.32%
-5.79USD-51.40%
-11.91USD-70.59%
-40.48USD+16.96%
-34.61USD+131.55%
-14.95USD+12.74%
-13.26USD+76.37%
-7.52USD+35.64%
-5.54USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Clearside Biomedical Stock analysis

What does Clearside Biomedical do? Clearside Biomedical, Inc. generates revenue through the development of drug therapies for blinding eye diseases, targeting the retina, choroid, and sclera. The company’s lead product candidate, XIPERE, is a proprietary, preservative-free suspension of the corticosteroid triamcinolone acetonide administered via suprachoroidal injection. This clinical stage biopharmaceutical firm focuses on treating conditions affecting these specific eye components to restore or preserve vision. The business model relies on advancing its proprietary therapies through clinical development rather than immediate commercial sales. By concentrating on the retina, choroid, and sclera, Clearside Biomedical, Inc. addresses critical anatomical areas involved in visual health. The company operates from its headquarters in Alpharetta, Georgia, with a dedicated team supporting its research and development efforts. Financial viability is tied to the successful progression of its drug candidates, particularly XIPERE, which utilizes a unique delivery method for triamcinolone acetonide. The firm engages in the biopharmaceutical sector by developing treatments for diseases that impact the structural and functional integrity of the eye. Its strategy centers on innovation in drug formulation and administration to treat blinding conditions effectively. Clearside Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Clearside Biomedical stock

EBIT per Share of Clearside Biomedical is -5.87 USD in 2024.

EBIT per Share of Clearside Biomedical changed from -6.03 USD to -5.87 USD, representing a -2.64% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Clearside Biomedical since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Clearside Biomedical

All Key Metrics — Clearside Biomedical